Case Study: Automating Prior Auth Across 8 Specialties in a Multi-Specialty Group

Prior authorization has become the single most time-consuming administrative burden in outpatient medicine. For single-specialty practices, the challenge is manageable — the authorization rules are confined to one clinical domain, the procedures requiring auth are well-known, and the staff develops payer-specific expertise through repetition. For multi-specialty groups, prior authorization becomes an entirely different problem. Eight specialties means eight sets of authorization rules, eight sets of clinical criteria, eight sets of payer-specific requirements, and a volume of authorization requests that overwhelms any manually managed process.

This case study examines how a 45-provider multi-specialty group — spanning cardiology, orthopedics, oncology, neurology, gastroenterology, urology, pain management, and dermatology — automated prior authorization processing across all specialties, reducing turnaround from 4.2 days to 4.2 hours, eliminating 85% of manual auth work, and recovering $1.6 million in annual revenue that had been lost to authorization-related problems. The results represent aggregate outcomes observed over a 14-month implementation period.

Note: Specific metrics in this case study are representative figures based on composite customer outcomes. Individual results vary based on practice size, payer mix, and baseline performance.

Results at a Glance

Metric	Before	After	Change
Average auth turnaround time	4.2 days	4.2 hours	-96%
Auths fully automated	0%	85%	+85 pts
Auth expiration rate	14%	2%	-86%
Procedure cancellations (auth-related)	9%	1.5%	-83%
Auth FTEs	6	2	4 redeployed
Auth-related revenue leakage	$2.1M/year	$500K/year	-76%
Annualized revenue recovered	—	$1.6M	—
Patient auth-related complaints	22/month	3/month	-86%

The Challenge: 6 FTEs Doing Nothing but Prior Auth

The Group's Operating Environment

The 45-provider group operated across 6 locations in a mid-sized metropolitan market. The practice included 7 cardiologists, 6 orthopedic surgeons, 5 oncologists, 5 neurologists, 6 gastroenterologists, 5 urologists, 6 pain management physicians, and 5 dermatologists. The group contracted with 38 commercial payers and plans, Medicare, three Medicare Advantage plans, and two Medicaid managed care organizations.

The payer mix was 32% commercial, 28% Medicare (traditional), 22% Medicare Advantage, 12% Medicaid, and 6% self-pay/other. Annual revenue was approximately $62 million across all specialties.

The Authorization Workload

The group processed approximately 1,800 prior authorization requests per month. This volume was driven by the authorization-intensive nature of the specialties involved:

• Cardiology (380 auths/month): Nuclear stress tests, cardiac MRI, cardiac CT angiography, echocardiograms (some MA plans), catheterization procedures
• Orthopedics (310 auths/month): Advanced imaging (MRI), surgical procedures (joint replacements, arthroscopies), DME (braces, orthotics), physical therapy referrals beyond initial visits
• Oncology (290 auths/month): Chemotherapy regimens, PET scans, targeted therapy and immunotherapy agents, radiation therapy, genetic testing
• Neurology (195 auths/month): MRI studies, EEG monitoring, Botox injections, specialty medications (MS drugs, anti-seizure medications), nerve conduction studies
• Gastroenterology (120 auths/month): Colonoscopies (some plans for non-screening), advanced endoscopic procedures, biologic medications (Crohn's, UC), capsule endoscopy
• Urology (105 auths/month): Cystoscopy, prostate procedures, advanced imaging, surgical procedures, specialty medications
• Pain management (240 auths/month): Epidural steroid injections, facet joint injections, nerve blocks, spinal cord stimulator trials, radiofrequency ablation, medication management
• Dermatology (160 auths/month): Biologic medications (psoriasis, eczema), Mohs surgery, phototherapy sessions, specialty compounded medications

Six full-time employees — one per roughly 300 authorization requests per month — managed the entire authorization workload. Their salaries, benefits, and overhead totaled approximately $480,000 annually.

Where the Process Was Failing

The 6-person authorization team worked diligently, but the structural complexity of multi-specialty prior auth overwhelmed a manual process in predictable ways.

Average turnaround of 4.2 days. From the time a physician ordered a procedure or medication requiring authorization to the time the authorization was approved (or denied), the average elapsed time was 4.2 days. This included time to determine whether auth was required (often uncertain for less common procedures or newer payer plans), time to compile the clinical documentation supporting the request, time to submit the request through the payer's preferred channel, and time waiting for the payer's response. The 4.2-day average masked significant variation: straightforward imaging authorizations averaged 2.1 days, while oncology drug authorizations averaged 6.8 days.

14% of authorizations expiring before the procedure. This was the group's most expensive authorization failure. An authorization was obtained, the procedure was scheduled, but the authorization expired before the procedure was performed — due to scheduling backlogs, patient rescheduling, or simply the authorization's valid window being too short for the practice's scheduling reality. When an authorization expired, the options were all costly: re-request the authorization (adding days of delay), perform the procedure without authorization (risking denial), or cancel the procedure (losing the revenue and frustrating the patient).

Across 1,800 monthly authorizations, 252 expired before use. At an average procedure value of $1,800, expired authorizations put $454,000 in monthly revenue at risk. Not all of that revenue was lost — many expirations were caught and re-authorized in time — but the group estimated that expired authorizations were the root cause of approximately $680,000 in annual revenue loss.

9% of scheduled procedures canceled due to auth issues. This was the patient-facing consequence of authorization failures. Nine percent of scheduled procedures — approximately 160 per month — were canceled or rescheduled because authorization had not been obtained, had been denied, or had expired. Each cancellation created a cascade of problems: the patient was inconvenienced (or, in the case of oncology patients, delayed in receiving treatment), the schedule slot went unfilled (lost revenue), and the administrative team had to rebook the patient while resolving the authorization issue.

The group estimated that each cancellation cost an average of $1,350 in lost revenue (accounting for the fact that most patients were eventually rescheduled, but some sought care elsewhere or delayed treatment). At 160 cancellations per month, the annual revenue impact from cancellations was approximately $2.6 million gross, with a net loss of approximately $860,000 after accounting for rescheduled patients.

Specialty-specific expertise fragmentation. The 6 authorization specialists each handled 1-2 specialties, developing expertise in the authorization requirements for their assigned departments. This specialization was efficient in theory but fragile in practice. When an auth specialist was out — sick, on vacation, or during turnover — their specialty's authorizations stalled. The remaining specialists didn't have the specialty-specific clinical knowledge to efficiently compile auth requests for unfamiliar specialties. Oncology drug authorizations, for example, required understanding of treatment protocols, lines of therapy, and clinical trial eligibility that a specialist accustomed to orthopedic imaging auths couldn't navigate without significant research time.

Staff turnover in the auth team averaged 33% annually. The work was repetitive, the payer interactions were frustrating, and the pressure from physicians whose patients were waiting for authorization was relentless. Each departure triggered a 3-4 month learning curve for the replacement, during which authorization throughput for the affected specialty declined measurably.

The $2.1 Million Revenue Leakage

The group's CFO quantified the total annual revenue leakage attributable to authorization-related problems:

Revenue Leakage Source	Annual Impact
Expired authorization write-offs	$680K
Procedure cancellation losses (net)	$860K
Auth denial write-offs (services rendered without auth)	$320K
Administrative rework costs	$240K
Total authorization-related leakage	$2.1M

This $2.1 million represented 3.4% of the group's total annual revenue — lost not to clinical issues or payer contract terms, but to administrative process failures in a single workflow.

The Solution: QuickAuth Across All 8 Specialties

The group deployed QuickAuth, QuickIntell's AI-powered prior authorization platform, across all 8 specialties with payer-specific authorization requirement databases covering the group's complete payer portfolio.

The Core Architecture

QuickAuth addressed the authorization challenge at three levels: determination (does this service require auth?), submission (compile and submit the request), and management (track status, prevent expiration, escalate denials).

Authorization determination engine. QuickAuth maintained a continuously updated database of authorization requirements at the plan level — not just the payer level. This distinction was critical for the group's multi-payer environment. A procedure might require authorization under a payer's HMO plan but not under its PPO plan, or require auth under one Medicare Advantage product but not another from the same insurance carrier.

When a physician ordered a service, QuickAuth automatically checked the patient's specific insurance plan against the authorization database and returned one of four results: authorization required (with clinical criteria needed), authorization not required, authorization status unknown (triggering a real-time eligibility check), or service not covered under the patient's plan (alerting staff before the service was rendered).

The determination engine covered 97.3% of the group's payer-plan combinations within 60 days of deployment. The remaining 2.7% — primarily small regional plans and out-of-area coverage — were flagged for manual verification.

Clinical documentation compilation. For services requiring authorization, QuickAuth automatically compiled supporting clinical information from the EHR — diagnoses, prior treatments, lab results, imaging findings, medication history — and applied specialty-specific templates aligned with each payer's clinical criteria. An oncology drug auth included cancer stage, lines of therapy, and NCCN guideline alignment; an orthopedic MRI auth included conservative treatment history and functional limitations; a pain management auth included prior injection history and treatment failure documentation.

Payer-specific submission routing. QuickAuth submitted through each payer's preferred channel — electronic portal API (22 payers), automated fax, or phone-based submission with pre-populated forms — ensuring format compliance across the entire payer portfolio.

Specialty-Specific Configuration

QuickAuth required specialty-specific configuration for each department's authorization nuances. Oncology was the most complex, requiring treatment protocol awareness, line-of-therapy tracking, biosimilar differentiation, and authorization validity monitoring for multi-cycle chemotherapy regimens. Pain management required batch-submission logic for treatment series and cumulative procedure count tracking against payer-imposed limits. Orthopedic surgical authorizations required automated compilation of conservative treatment histories and documentation gap identification before submission.

Implementation: 12-Week Phased Rollout

Phase 1: Pain Management and Cardiology (Weeks 1-4)

Pain management and cardiology were selected as the first specialties because they had the highest authorization volume relative to provider count, and their authorization requirements were among the most standardized. QuickAuth was deployed in shadow mode for the first two weeks — processing authorizations alongside the manual process and comparing outcomes.

During shadow mode, QuickAuth correctly determined authorization requirements 94.8% of the time. The 5.2% error rate was concentrated in three areas: a recently acquired Medicare Advantage plan whose requirements weren't in the initial database, a commercial payer that had changed its cardiac imaging auth policy without notification, and a pain management procedure code that had been added to a payer's auth requirement list in the prior quarter.

These gaps were corrected by week 3, and QuickAuth was activated for live authorization processing in pain management and cardiology by week 4.

Week 4 results: 78% of pain management and cardiology auths fully automated. Average turnaround for automated auths: 3.1 hours. Auth specialist time spent on these two specialties reduced by 72%.

Phase 2: Orthopedics, Neurology, and Gastroenterology (Weeks 4-8)

The second phase added three specialties with moderate authorization complexity. Orthopedic surgical authorizations required the most configuration work due to the conservative treatment documentation requirements.

The implementation team identified a significant efficiency gain during this phase: many payers used the same authorization portal and clinical criteria framework across multiple specialties. Configuration work done for cardiology imaging authorizations in Phase 1 applied directly to neurology and gastroenterology imaging authorizations, reducing the Phase 2 configuration effort by approximately 35%.

Week 8 results: 82% of authorizations across 5 specialties fully automated. Average turnaround: 3.8 hours. Auth FTE time across all 5 specialties reduced to 2.5 FTE-equivalents (down from the 4.5 FTEs who had previously covered these departments).

Phase 3: Oncology, Urology, and Dermatology (Weeks 8-12)

The final phase added the remaining three specialties. Oncology was the most implementation-intensive, requiring treatment protocol mapping and line-of-therapy tracking configuration. Urology and dermatology were relatively straightforward, with authorization requirements concentrated in specific procedure and medication categories.

The oncology configuration required an additional two weeks of parallel processing beyond the standard timeline, extending through week 14 before full activation. The complexity stemmed from three factors: the wide variation in oncology drug authorization requirements across payers, the need to integrate with the group's specialty pharmacy for medication-specific authorizations, and the clinical sensitivity of oncology treatment delays (making authorization accuracy more critical than speed).

Week 12 results (week 14 for oncology): 85% of all authorizations across all 8 specialties fully automated. Average turnaround: 4.2 hours. Auth FTEs effectively operating at 2 FTE-equivalents.

Results: The Full Impact After 14 Months

Authorization Turnaround: 4.2 Days to 4.2 Hours

The 96% reduction in average authorization turnaround was the headline metric, but the distribution of turnaround times was equally significant.

Turnaround Category	Before	After
Same-day authorization	12%	91%
1-2 day authorization	28%	6%
3-5 day authorization	41%	2%
5+ day authorization	19%	1%

Under the manual process, only 12% of authorizations were completed on the same day they were requested. After QuickAuth deployment, 91% were completed the same day — most within hours of the physician's order. The 9% that took longer than same-day were concentrated in three categories: oncology drug authorizations requiring payer medical director review, surgical authorizations requiring peer-to-peer discussion, and authorizations from payers without electronic submission portals where fax turnaround was inherently slower.

The impact on patient care was substantial. Patients no longer waited days to learn whether their recommended procedure or medication was authorized. Scheduling delays caused by pending authorizations were largely eliminated. Physicians reported that the authorization bottleneck — previously a daily source of frustration — had become a non-issue in their clinical workflow.

Authorization Expiration: 14% to 2%

QuickAuth's expiration prevention worked on three fronts: proactive scheduling alignment (comparing authorization validity windows to scheduled procedure dates and alerting when mismatched), expiration countdown alerts (escalating notifications at 30, 14, 7, and 3 days before expiration), and automatic re-authorization (initiating renewal requests when authorizations expired with the patient still needing the service). The remaining 2% expiration rate was concentrated in patient-driven factors — declined procedures, insurance plan changes, and hospitalizations preventing appointments.

Procedure Cancellations: 9% to 1.5%

Auth-related procedure cancellations dropped from approximately 160 per month to 27 per month. The remaining cancellations were primarily attributable to authorization denials that could not be overturned through appeal (typically cases where the payer determined the service was not medically necessary based on the clinical documentation), and late-notice insurance plan changes not detected by the eligibility verification system.

The reduction in cancellations had a secondary benefit: schedule utilization improved. Previously, the 160 monthly cancellations created empty schedule slots that were difficult to fill on short notice. With cancellations reduced to 27, the group's schedule utilization improved from 86% to 93%, generating an estimated $340,000 in incremental revenue from procedures filling previously wasted slots.

Staff Redeployment: 6 FTEs to 2

Four authorization specialists were redeployed: one to patient financial counseling (improving point-of-service collections), one to referral coordination (reducing patient leakage), one to payer contract analysis (identifying unfavorable contract terms), and one to clinical documentation improvement (creating a feedback loop between better documentation and faster auth approvals). The two remaining specialists handled the 15% of authorizations requiring human intervention — peer-to-peer reviews, complex oncology drug auths, and appeals.

Revenue Recovery: $1.6 Million Annualized

Revenue Recovery Source	Annual Impact
Eliminated auth expiration losses	$580K
Reduced procedure cancellation losses	$490K
Eliminated auth-gap denial write-offs	$290K
Schedule utilization improvement	$340K
Labor savings from FTE redeployment	$320K
Administrative rework reduction	$180K
Total annualized recovery	$2.2M gross / $1.6M net

The $1.6 million net recovery figure accounts for the cost of the QuickAuth platform, including licensing fees, implementation services, integration costs, and ongoing support — approximately $580,000 in the first year and $420,000 annually thereafter.

Specialty-Specific Outcomes

Specialty	Auth Volume/Month	Automation Rate	Avg. Turnaround	Denial Rate Change
Cardiology	380	92%	2.8 hrs	-84%
Orthopedics	310	84%	4.6 hrs	-78%
Oncology	290	71%	8.2 hrs	-62%
Pain Management	240	93%	2.1 hrs	-89%
Neurology	195	87%	3.8 hrs	-81%
Dermatology	160	89%	3.1 hrs	-85%
Gastroenterology	120	88%	3.4 hrs	-80%
Urology	105	86%	3.9 hrs	-77%

Oncology had the lowest automation rate (71%) and longest average turnaround (8.2 hours) because oncology drug authorizations frequently required medical director review and clinical complexity that exceeded what fully automated submission could address. Even so, the improvement over the manual process — where oncology auths averaged 6.8 days — was dramatic.

Pain management and cardiology had the highest automation rates (93% and 92%) because their authorization requirements were the most standardized and the clinical criteria the most objectively measurable. These two specialties were also the first deployed, giving QuickAuth the longest learning period for their payer-specific patterns.

Key Takeaways for Multi-Specialty Groups

1. Prior Authorization Is a Scale Problem, Not a Skill Problem

The group's 6 authorization specialists were highly skilled at their work. The problem was that 1,800 monthly authorizations across 8 specialties and 38+ payers created a combinatorial workload that no team of 6 could manage without gaps. Adding more staff would have provided temporary relief, but the fundamental mismatch between workload complexity and human processing capacity would have reasserted itself with each new payer contract or specialty authorization requirement. Automation addressed the scale problem that additional staffing could not.

2. Authorization Expiration Is the Most Expensive Auth Failure Mode

The group had focused its improvement efforts on reducing authorization denials — getting the auth approved in the first place. But the data revealed that authorization expirations were a larger source of revenue loss than denials. An authorization that is obtained and then expires represents double waste: the cost of obtaining the original authorization plus the cost of the expired service (cancellation, rescheduling, or re-authorization). Groups evaluating their authorization process should measure expiration rates alongside denial rates.

3. Multi-Specialty Auth Automation Creates Cross-Specialty Efficiencies

A significant implementation finding was that payer-specific configuration work done for one specialty often applied to others. The payer's electronic portal, clinical criteria framework, and submission requirements were typically consistent across specialties — even though the clinical content of the authorization differed. This meant that the marginal cost of adding each additional specialty to QuickAuth decreased: the first two specialties required approximately 60% of the total configuration effort, with the remaining six specialties sharing the remaining 40%. Multi-specialty groups benefit from this economy of scope more than single-specialty practices.

4. Redeployed Auth Staff Create Disproportionate Value Elsewhere

The four redeployed authorization specialists weren't just a cost saving — they were a strategic gain. The patient financial counselor improved point-of-service collections by 22%. The referral coordinator reduced patient leakage by an estimated 8%. The payer contract analyst identified $180,000 in unfavorable contract terms during her first year. The CDI specialist improved documentation quality scores by 15%. These roles had been unfilled for years because the group couldn't justify pulling staff away from authorization processing. Automation freed the staff to do work that a manual auth process never would have allowed.

5. Oncology Auth Automation Has Different Expectations

Groups should expect lower automation rates for oncology drug authorizations than for imaging or procedural authorizations. Oncology drug authorizations require clinical nuance — line-of-therapy determination, biomarker interpretation, clinical trial eligibility assessment — that exceeds current automation capabilities for full end-to-end processing. The appropriate expectation for oncology is semi-automation: the system compiles the clinical documentation, determines the authorization requirement, submits the request, and tracks the response, but a human reviews the submission for clinical accuracy before it goes to the payer. Even at 71% automation, this approach reduced oncology auth turnaround from 6.8 days to 8.2 hours — a transformation for patients whose treatment depends on timely authorization.

---

This case study presents representative outcomes based on aggregate customer data from multi-specialty groups using the QuickIntell platform. Individual results depend on group size, specialty mix, payer portfolio, and baseline authorization performance. To discuss how these results might apply to your organization, contact QuickIntell for a custom analysis.